Medical University of South Carolina - Cancer Center Support Grant

南卡罗来纳医科大学 - 癌症中心支持补助金

• 批准号: 8923675
• 负责人: Andrew S Kraft
• 金额: $ 14.74万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8923675
• 关键词: Academic Medical Centers; Address; Award; Biomedical Engineering; Biometry; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Immunology Science; Cells; Charge; Clinical; Clinical Trials; Coupling; Development; Diagnosis; Enrollment; Ensure; Extramural Activities; Funding; Head; Healthcare; Leadership; Malignant Neoplasms; Medical; Minority; Mission; Molecular; Movement; NCI Center for Cancer Research; National Cancer Institute; Oncogenes; Patients; Regulation; Research; Resources; Rural Population; Scientist; Secure; Services; South Carolina; Technology; Therapeutic; Therapy Evaluation; Tissues; Translational Research; Underserved Population; Universities; authority; base; biobank; cancer education; cellular imaging; college; drug discovery; innovation; medically underserved; molecular imaging; novel strategies; outreach; population based; programs; ranpirnase; rapid growth; research facility; treatment trial

DESCRIPTION (provided by applicant): The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation awarded in 2009 via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's leading academic medical center, MUSC is charged with building clinical, basic, translational, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in South Carolina. To accomplish this mission, the Director, Dr. Andrew S. Kraft, and the HCC senior leadership have established a robust, interdisciplinary base that now includes 122 cancer scientists from 5 MUSC colleges and 20 academic departments. Interdisciplinary, innovative research is driven through the organization of the HCC into four programs: Cancer Genes & Molecular Regulation, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by shared research resources, five of which are presented in this application: Lipidomics, Cell Evaluation & Therapy, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. The HCC also seeks CCSG support for its Clinical Trials Office which has spear-headed a dramatic 59% increase in accrual volume for interventional treatment trials over the last four years. Notably, 26% of patients enrolled onto interventional treatment trials in 2012 were minorities, representing a 45% increase in this project period. This has been promoted by HCC-led progressive outreach services and cancer education to South Carolinians, a largely rural population that includes some of the most medically underserved people in the US. Today, the HCC has $40.8M in annual total extramural research funding with $18.6M derived from the NCI, representing a 31% and 54% increase, respectively, since 2009. The HCC has successfully leveraged CCSG funding during the first project period and its NCI-designated Cancer Center status to continue the rapid growth of this Center. During the current project period, the HCC supported 34 strategic recruitments to the Center. The opening of two state-of-the-art research facilities at MUSC, the Bioengineering and Drug Discovery Buildings, has resulted in an additional 66,156 ft of HCC research space, bringing the total amount of space on campus under the HCC authority to 270,174 ft. The HCC has invested $5.3M since 2009 to introduce cutting-edge technologies and has secured another $3.8M in institutional commitments to increase the range of available resources. These impressive developments ensure that HCC scientists will continue their exemplary track record in making significant contributions to the understanding of cancer biology while coupling these findings to the development of novel approaches to cancer control, diagnosis, and treatment.

描述（由申请人提供）：南卡罗来纳医科大学（MUSC）的霍林斯癌症中心（HCC）寻求通过P30癌症中心支持拨款（CCSG）机制更新其2009年授予的国家癌症研究所（NCI）称号。作为南卡罗来纳州领先的学术医疗中心，MUSC负责建立临床、基础、转化和以人口为基础的研究项目，以解决该州重大的医疗保健需求。HCC的使命是减轻南卡罗来纳的癌症负担。为了完成这一使命，主任Andrew S. Kraft博士和HCC高级领导层建立了一个强大的跨学科基地，目前包括来自5个MUSC学院和20个学术部门的122名癌症科学家。